This finding provides a basis for development of novel approaches for treating CML by targeting OLFM4 or OLFM4-mediated signaling pathways in primitive leukemia cells. This evidence concerns the gene OLFM4 and chronic myelogenous leukemia, BCR-ABL1 positive.